News

Acadia Pharmaceuticals‘ Nuplazid (pimavanserin) is a reliable treatment to manage hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), but its high cost and restricted access may limit its use in clinical practice, a new study says. The review, “Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis,”…

Treatment with ADS-5102 (amantadine) significantly decreased levodopa-induced dyskinesia and off-time episodes in patients with Parkinson’s disease at three months, and maintained those benefits for another three months, according to results of a Phase 3  clinical trial that may prove pivotal in the medicine’s approval. Adamas Pharmaceuticals, the treatment’s developer, has filed a New Drug Application…

AFFiRiS’s new Parkinson’s vaccine, AFFITOPE PD03A, triggered a solid immune response against the alpha-Synuclein (aSyn) protein associated with the disease, according to a Phase 1 clinical trial. Patients also tolerated the therapy well, researchers said. Werner Poewe, a professor at Austria’s Medical University Insbruck, presented the results at the 21stInternational Congress…

Almost half of Americans said in a survey that awareness of Parkinson’s disease has increased in the past year due to Muhammad Ali’s long and inspirational fight against the disease. The results are from a national survey led by the Muhammad Ali Parkinson Center. The survey, which was…

NeuroDerm received a green light from the European Medicines Agency (EMA) for the main design elements of the amended iNDiGO trial evaluating ND0612 as a treatment for Parkinson’s disease in patients on levodopa with motor fluctuations. The letter NeuroDerm…

Forty-two percent of Parkinson’s patients who took ND0612H were able to eliminate periods during the day when their symptoms recurred because their therapy had worn off, according to a Phase 2 clinical trial. The 006 trial (NCT02577523) of NeuroDerm’s IV-delivered therapy dealt with what is known as Parkinson’s off time. The time…

CVT-301 significantly improves movement in Parkinson’s disease patients at times of the day when the impact of other therapies diminishes, according to a Phase 3 clinical trial. The impact of a Parkinson’s treatment varies during the day. It is often most effective right after a patient takes it, and least…

Australia’s GKC (Global Kinetics Corp.) has enrolled the first of more than 400 Parkinson’s patients in its APPRISE clinical trial — a multicenter, randomized study that will determine whether the Personal KinetiGraph (PKG) system is appropriate for identifying which patients need to change the clinical management of their disease. The trial,…

A strain of influenza commonly known as swine flu could trigger the development of Parkinson’s disease, according to a study in mice. Mice infected with the H1N1 strain lost a lot of their brain neurons, even long after the virus struck. Neuron loss is a hallmark of Parkinson’s. Importantly, vaccination against the…

Merz Neurosciences says two doses of its therapy Xeomin (incobotulinumtoxin A) effectively treat chronic drooling among patients with Parkinson’s disease and other illnesses. The company, a unit of Germany’s Merz Pharma, will present results from the SIAXI Phase 3 clinical trial (NCT02091739) June 7 at the 21st International Congress of Parkinson’s Disease…